Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Pharmacological interventions for prevention of weight gain in people with schizophrenia.The Cochrane database of systematic reviews · 2022
   Pooled it
2. Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials.The Journal of international medical research · 2018
   Pooled it
3. Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study).Early intervention in psychiatry · 2023
   Trial
4. Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study.International journal of environmental research and public health · 2021
   Trial
5. GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.Nature metabolism · 2025
   Article
6. Metformin for Overweight and Obese Children With Bipolar Spectrum Disorders Treated With Second-Generation Antipsychotics (MOBILITY): Protocol and Methodological Considerations for a Large Pragmatic Randomized Clinical Trial.JAACAP open · 2023
   Article
7. A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the Physical Health Assistance in Early Psychosis (PHAstER) study.BJPsych open · 2022
   Article
8. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2020
   Article
9. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research.Psychopharmacology · 2017
   Review
10. Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder.Journal of autism and developmental disorders · 2017
    Observational
11. Bipolar Spectrum Disorders in Male Youth: The Interplay between Symptom Severity, Inflammation, Steroid Secretion, and Body Composition.Frontiers in psychiatry · 2017
    Review
12. Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management.Adolescent health, medicine and therapeutics · 2014
    Review
13. Outpatient metformin management of obese individuals with schizophrenia.The primary care companion for CNS disorders · 2014
    Article

Corrections and comments

• Commented on by
  Metformin and Alzheimer's disease risk.2014
• Comment on
  Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.2013

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as